为您找到相关结果约500个

你是不是要搜索 期刊CD28/ICOS 点击跳转

Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naive

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical

The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype

ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell

Genetic diversity of CD14, CD28, CTLA-4 and ICOS gene promoter polymorphism in African and American sickle

Stratification Of Idiopathic Pulmonary Fibrosis Survival By Icos And Cd28 Surface Expression On T Cells

Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response

Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity

Polymorphisms of the Costimulatory Genes CTLA-4, CD28, PD-1, and ICOS and Outcome of Kidney Transplants

Investigation of ICOS, CD28 and CD80 polymorphisms with the risk of hepatocellular carcinoma: a case-control

Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CART Cell Antitumor Activity

Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOSand CD28 with Acazicolcept (ALPN-101)

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with

为您找到相关结果约500个

共500条页码: 1/34页15条/页